Cell-based flu shot beats current vaccine: study
Thursday 17 February 2011
Flu vaccines made from lab-grown cells work at least as well as those derived from viruses cultivated in chicken eggs, the preferred method for 50 years, according to a study released Wednesday.
The findings, reported in The Lancet, could help speed approval for the new technique in the United States, which has recently said healthy adults should also be inoculated against seasonal influenza.
Cell-based flu vaccines have major advantages over the traditional manufacturing process, including unlimited supply, a shorter production time, and an alternative for persons allergic to eggs.
They may also be better suited for developing a shield against the potential pandemic threat of a deadly H5N1 bird flu mutation.
But their effectiveness had yet to be fully tested in a large-scale clinical trial, according to the authors.
Noel Barrett, a researcher at the Biomedical Research Centre in Austria, and colleagues divided more than 7,000 volunteers in the United States, 18 to 49 years old, into two groups.
Participants in the first group were injected with a flu vaccine derived from lab-grown cells during the 2008-2009 influenza season, while the second group was given a placebo shot with no active ingredients.
The vaccine was nearly 80 percent effective in protecting against that year's flu strains, comparing favourably to a 73 percent rate for egg-based vaccines, as reported elsewhere.
There were no serious secondary effects, with only a few "mild and transient" problems registered.
"This study is the first published report of the clinical efficacy of an influenza vaccine derived from a Vero-cell-culture," the authors said, using the term for animal or human cell lines grown in the laboratory.
Cell-based flu vaccines have been approved for use in Europe, and were made in limited quantities before and during the 14-month World Health Organisation (WHO) H1N1 "swine flu" pandemic alert in 2009/2010.
The virus turned out to be less lethal than feared, and large stocks of hastily manufactured vaccine went unused.
But had the flu been more deadly - especially early in the flu season - it is unlikely that pharmaceutical companies could have kept up with demand using the egg-based method of fabrication, experts say.
In egg culture, flu viruses are injected into chicken egg embryos, where they multiply. After several days of incubation a machine opens the egg and harvests the virus, which is then purified and chemically killed.
On average it takes one or two eggs to produce a single dose of annual flu vaccine.
In cell culture, the virus is grown in animal or human cells, which are available in unlimited supply.
In August 2010, the WHO said swine flu - which has to date claimed more than 18,400 lives worldwide - had "largely run its course", declaring an end to the pandemic.
The H1N1 virus is now regarded as part of seasonal influenza and protection is included in standard seasonal flu vaccines.
Life & Style blogs
The best Oscar dresses of all time
The remarkable archaeological underwater discovery that could open up a new chapter in the study of European and British prehistory
Google Plus might be dead, as ‘Streams’ and ‘Photos’ take its place
Mother's Day 2015: When is it – and how did it first come about?
Samsung Galaxy S6 and Galaxy S6 edge launch and review: wireless charging and new case see Samsung ready to take on Apple's iPhone
- 1 End of the licence fee: BBC to back radical overhaul of how it is funded
- 2 Raif Badawi, the Saudi Arabian blogger sentenced to 1,000 lashes, may now face death penalty
- 3 PornHub turns masturbation into energy in bid to save the planet
- 4 Dakota Johnson's 'It's only Isis' Saturday Night Live sketch sparks controversy
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...
Negotiable: Recruitment Genius: One of the North West's leading web hosting pr...
£28000 - £30000 per annum: Recruitment Genius: Based in Grantham, Lincolnshire...
Negotiable: Recruitment Genius: This accelerated growth ISP company is current...